Cingulate Inc. (NASDAQ:CINGW) Sees Large Decline in Short Interest

Cingulate Inc. (NASDAQ:CINGW – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 402 shares, a decrease of 96.3% from the May 31st total of 10,882 shares. Based on an average daily volume of 13,143 shares, the short-interest ratio is currently 0.0 days.

Cingulate Price Performance

NASDAQ CINGW remained flat at $0.02 during mid-day trading on Thursday. Cingulate has a fifty-two week low of $0.02 and a fifty-two week high of $0.17. The stock has a 50 day simple moving average of $0.02 and a 200-day simple moving average of $0.05.

Cingulate Company Profile

(Get Free Report)

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

Featured Stories

• Five stocks we like better than Cingulate
• MDA Space Targets US Defense Market With $620M Acquisition
• Carnival’s Second Quarter: Is the Stock Still Complicated?
• Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
• Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal